Search Results - neurologic+disease

42 Results Sort By:
Inhibitors of TRIP8b for Novel Mood Disorder Therapeutics
SHORT DESCRIPTION Novel inhibitors that disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism for treatment of mood disorders. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Dane Chetkovich Ye Han Iredia Iyamu Kyle Lyman *...
Published: 6/17/2026   |   Updated: 6/17/2026   |   Inventor(s):  
Keywords(s): Antidepressant, BIO2026, Depression, Mood disorder, Neurologic disease, Neurology, Psychiatric disorder, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2016-137B INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...
Published: 6/17/2026   |   Updated: 6/16/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, HD - Huntington's Disease, Melanoma, Neurodegenerative disease, Neuroinflammation, Neurologic disease, nNOS, PD - Parkinson's Disease, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
A CSF-Derived Therapy for Psychiatric Disorders
SHORT DESCRIPTION A synthetic soluble ⍺2δ-1-Fc protein to restore brain function in schizophrenia and autism. INVENTORS Peter Penzes* Northwestern University Feinberg School of Medicine, Department of Physiology Marc Dos Santos * Principal Investigator NU Tech ID: NU 2023-196 IP STATUS US...
Published: 6/16/2026   |   Updated: 6/10/2026   |   Inventor(s):  
Keywords(s): ASD - Autism Spectrum Disorder, BIO2026, Biologic, Neurologic disease, Neurology, PSD - Psychotic spectrum disorder, Psychiatric disorder, Schizophrenia, Therapeutics
Category(s): Life Sciences > Therapeutics
Novel Aminotransferase Inhibitor Platform for the Treatment of Cancer and Neurological Disorders
SHORT DESCRIPTION Novel Aminotransferase Mechanism-Based Inhibitor (MBI) Platform Targeting OAT and GABA-AT as Novel Treatments for Cancer and Neurological Disorders. INVENTORS Richard Silverman* Weinberg College of Arts and Sciences, Department of Chemistry * Principal Investigator DEVELOPMENT...
Published: 6/17/2026   |   Updated: 6/1/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Epilepsy, Gastric cancer, Liver cancer, Lung cancer, Neurodegenerative disease, Neurologic disease, Neurology, Pancreatic cancer, PD - Parkinson's Disease, Psychiatric disorder, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Antisense Oligonucleotides to Prevent Genetic Mis-Splicing for ALS/FTD Therapeutics
SHORT DESCRIPTION Antisense oligonucleotides (ASOs) that correct TDP‑43–dependent mis‑splicing of KCNQ2 thereby reducing neuronal hyperexcitability in ALS/FTD and related TDP‑43 proteinopathies. INVENTORS Evangelos Kiskinis* Northwestern University Feinberg School of Medicine, Department of Neurology Jonathan...
Published: 6/16/2026   |   Updated: 5/7/2026   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, BIO2026, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurologic disease, Neurology, Nucleic Acids, Rare diseases, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Northwestern Startup: Acumen Pharmaceuticals, Inc.
Founded: 1996 Northwestern Inventor: William Klein Weinberg College of Arts and Sciences Department of Neurobiology and Physiology Grant Krafft Feinberg School of Medicine Department of Molecular Pharmacology and Biological Chemistry Acumen Pharmaceuticals develops therapeutics for Alzheimer's Disease (AD) based upon the discovery and characterization...
Published: 6/22/2026   |   Updated: 5/7/2026   |   Inventor(s):  
Keywords(s): Antibody, Neurodegenerative disease, Neurologic disease, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Healthcare Devices, Tools & IT
GDNF-Mimetic Self-Assembling Supramolecular Nanostructure to Enhance Survival and Function of Dopaminergic Neurons for Treatment of Parkinson's Disease
NU 2024-175 SHORT DESCRIPTION A self-assembling bioactive matrix that presents GDNF-mimetic peptides to support the viability, maturation, and function of dopaminergic neurons in cell replacement therapy for treatment of Parkinson’s Disease. INVENTORS Samuel Stupp* Weinberg College of Arts and Sciences, Department...
Published: 6/16/2026   |   Updated: 4/30/2026   |   Inventor(s):  
Keywords(s): BIO2026, Biologic, Biomaterials, Cell delivery, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Scaffold, SCI - Spinal cord injury, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT > Neurology
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU Tech ID: NU 2025-212 IP...
Published: 6/16/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, BIO2026, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
Selective PAD2 Inhibitors for Neuroprotection in Traumatic Brain Injury
SHORT DESCRIPTION Novel PAD2-selective inhibitor platform targeting neuroinflammation to support both acute neuroprotection and long-term functional recovery as a first-in-class treatment of traumatic brain injury. INVENTORS Hasan Alam* Northwestern University Feinberg School of Medicine, Department of Surgery (Trauma...
Published: 6/16/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): BIO2026, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Neurodegenerative disease, Neuroinflammation, Neurologic disease, Neurology, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets. INVENTORS Shana Kelley* Weinberg College of Arts & Sciences, Department of Chemistry Yi Li * Principal Investigator NU Tech ID: NU 2025-050 IP...
Published: 6/16/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
1 2 3 4 5